RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultragenyx Pharmaceutical Inc is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock has bearish technical momentum, mixed-to-negative analyst revisions, and no strong proprietary buy signal. While the company still has meaningful pipeline upside, the current setup is better suited for waiting than for an impatient entry. My direct view: hold and do not buy today.
RARE is trading pre-market at 23.43, up 0.73%, with broader market pre-market also slightly positive. Technically, the stock remains weak: MACD histogram is -0.323 and still below zero, RSI_6 at 36.361 shows weak but not oversold momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key levels show pivot resistance at 24.223, with upside barriers at 25.919 and 26.967, while support sits at 22.527 and 21.479. Overall trend is still downtrend/consolidation rather than a confirmed reversal. The short-term pattern model suggests only modest near-term upside.
Potential catalysts include upcoming pipeline and regulatory events, especially GTX-102 Phase 3 ASPIRE data, and the company’s two PDUFAs for DTX401 and UX111, which could create monetizable PRV opportunities. Analyst commentary also notes possible upside if Angelman syndrome data are positive. The company continues to have a multi-asset rare disease pipeline with event-driven upside.
Recent analyst actions have trended lower in price targets, including cuts from Evercore ISI, Wedbush, Guggenheim, Barclays, and Goldman Sachs. Goldman downgraded the stock to Neutral after the setrusumab Phase 3 miss, which materially hurt sentiment. Wedbush noted a top-line miss, and despite maintaining guidance, near-term visibility remains tied to clinical readouts. There is also no supportive insider or hedge fund accumulation trend, and no recent congress or influential figure trading activity.
No latest quarter financial snapshot was available due to an input error, so a quarter-by-quarter financial assessment cannot be made from the provided data. The only financial guidance-related commentary in the analyst notes suggests management reiterated FY26 revenue guidance and Wedbush continues to expect profitability in 2027. That implies the business still has a path to future improvement, but no verified latest-quarter growth figures were provided. Latest quarter season: not available from the data.
Analyst sentiment is mixed but has recently turned more cautious. Evercore ISI kept Outperform but trimmed its target to $33, Wedbush kept Neutral and cut to $26, and Guggenheim kept Buy but lowered target to $43. Barclays stayed Overweight with a lower $43 target, while Morgan Stanley remains Outperform and sees favorable asymmetry into GTX-102 data. Against that, Goldman Sachs downgraded to Neutral with a sharp target cut to $25 after the setrusumab miss. Wall Street’s pro case is pipeline-driven optionality and asymmetric upside from positive clinical data; the con case is execution risk, recent trial disappointment, and reduced near-term fundamental support.
